Furthermore, investing in just one AI stock also isn't a great move, as putting all your eggs in one basket is an easy way to miss out on a trend as massive as AI if the pick fails. What this one pick boils down to is my favorite AI stock, which is the one I will add to first if the market suddenly drops. If I had to only own one, I'd likely choose Nvidia (NASDAQ: NVDA).

Niccol, the former Chipotle Mexican Grill head, who is four months into his new role at Starbucks has set forth a raft of measures to improve the coffee chain's business, which took a hit from increased competition and weakening demand in the U.S. and China. "Our size and structure can slow us down, with too many layers, managers of small teams and roles focused primarily on coordinating work," Niccol said in a statement, adding that he will examine the role, structure and size of support teams globally.

The US Department of Justice (DOJ) has filed a lawsuit against Walgreens (WBA), one of the nation's largest pharmacy chains, alleging widespread prescription drug practice violations. According to the DOJ, Walgreens improperly dispensed millions of prescriptions from August 2012 to the present day that either lacked "legitimate medical purpose" or were otherwise invalid. Yahoo Finance anchors Josh Lipton and Alexandra Canal dive into the details, discussing the fines the pharmacy giant would face if found liable — up to $80,850 per unlawful prescription. To watch more expert insights and analysis on the latest market action, check out more Market Domination here. This post was written by Angel Smith

Starbucks said Friday it plans an unspecified number of layoffs as it restructures its corporate staff. In a letter to employees, Starbucks Chairman and CEO Brian Niccol said the Seattle coffee giant needs to ensure all work has a clear and accountable owner who can make decisions. “Our size and structure can slow us down, with too many layers, managers of small teams and roles focused primarily on coordinating work,” Niccol wrote.

(Bloomberg) -- Moderna Inc. was awarded an additional $590 million from the US government to help the company develop a vaccine aimed at protecting people from bird flu.Most Read from BloombergThese Homes Withstood the LA Fires. Architects Explain WhyNYC Commuters Get New Way to Dodge Traffic: $95 Helicopter RidesScaramucci, Ackman Donate to Whitney Tilson’s NYC Mayoral RunIn a City of Sprawl, Wildfire Evacuation Is Getting HarderWill Americans Ever Lose Their Taste for Telework?The funding will

Tesla (TSLA) stock jumped again on Wednesday, leading the market upwards following some positive inflation data. However, this only served to make the electric vehicle (EV) maker more expensive, with the stock now trading at 160x forward earnings. Despite being broadly supportive of Elon Musk’s business endeavors, I’m bearish on Tesla simply because the valuation is incredibly hard to justify and Musk’s plans hard to quantify. Tesla’s Plans Remain Ambitious I’m bearish on Tesla, but not because

The S&P 500 jumped 1% on Friday, Jan. 17, 2025, heading into the long weekend on a high note as prospects rebounded for additional interest-rate cuts in 2025.

Coinbase (COIN) shares gain following reports that President-elect Donald Trump will make crypto a top priority in the early days of his second term. Alexandra Canal and Josh Lipton examine bitcoin's (BTC-USD) move higher ahead of Trump's inauguration and how it has lifted Coinbase and other crypto proxies. To watch more expert insights and analysis on the latest market action, check out more Market Domination here. This post was written by Naomi Buchanan.

A Tesla Inc (NASDAQ:TSLA) analyst highlighted the monetization opportunities for the company with its robotaxis and FSD. The Tesla Analyst: Goldman Sachs analyst Mark Delaney maintained a Neutral rating on Tesla with a $345 price target. The Analyst ...

CAMBRIDGE, MA / ACCESS Newswire / January 17, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced ongoing support from the U.S. Department of Health and Human Services (HHS) to accelerate the development of mRNA-based pandemic influenza vaccines. The ...